Skip to main content
. 2020 Sep 21;11(9):e00202. doi: 10.14309/ctg.0000000000000202

Figure 4.

Figure 4.

SMAD family member 4 (SMAD4) expression and correlation with clinical outcomes in EAC. (a) Immunohistochemical profile of a case with SMAD4 loss in tumor cells vs normally expressed SMAD4 in non-neoplastic glands and in stromal cells (upper left corner) (hematoxylin was used as a counterstain) (×20). (b) EAC grouped according to cancer with high SMAD4 (<30% loss of protein expression; green bars) and low SMAD4 (>30% loss of protein expression; blue bars) and disease recurrence (Fisher exact test; P = 0.015). EAC, esophageal adenocarcinoma.